Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation is scheduled for Monday, September 8, 2025, from 4:00 to 4:30 p.m. ET.
The company, which focuses on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, will make the presentation available via webcast. Investors can access the webcast through the "Events and Presentations" section of Longeveron's website, with replay access available for 180 days following the conference.
Longeveron (NASDAQ: LGVN), una biotech in fase clinica specializzata nella medicina rigenerativa, presenterà al H.C. Wainwright 27th Annual Global Investment Conference a New York City. La presentazione si terrà lunedì 8 settembre 2025, dalle 16:00 alle 16:30 ET.
L'azienda, che sviluppa terapie cellulari per condizioni pediatriche rare e per patologie correlate all'invecchiamento cronico, renderà la presentazione disponibile in webcast. Gli investitori potranno accedere al webcast dalla sezione "Events and Presentations" del sito di Longeveron; la registrazione sarà disponibile in replica per 180 giorni dopo la conferenza.
Longeveron (NASDAQ: LGVN), una biotecnológica en fase clínica dedicada a la medicina regenerativa, presentará en la H.C. Wainwright 27th Annual Global Investment Conference en Nueva York. La presentación está programada para el lunes 8 de septiembre de 2025, de 4:00 a 4:30 p.m. ET.
La compañía, enfocada en desarrollar terapias celulares para enfermedades pediátricas raras y afecciones crónicas relacionadas con el envejecimiento, transmitirá la presentación por webcast. Los inversores podrán acceder al webcast en la sección "Events and Presentations" del sitio web de Longeveron; la reproducción estará disponible durante 180 días después de la conferencia.
Longeveron (NASDAQ: LGVN)은 임상 단계의 재생의학 바이오테크 기업으로, 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference에서 발표할 예정입니다. 발표 일정은 2025년 9월 8일 월요일 동부시간 오후 4시부터 4시 30분까지입니다.
희귀 소아 질환 및 만성 노화 관련 상태에 대한 세포치료제를 개발하는 이 회사는 발표를 웹캐스트로 제공할 예정입니다. 투자자들은 Longeveron 웹사이트의 "Events and Presentations" 섹션을 통해 웹캐스트에 접속할 수 있으며, 회의 후 180일 동안 다시보기로 시청할 수 있습니다.
Longeveron (NASDAQ: LGVN), une société de biotechnologie en phase clinique spécialisée en médecine régénérative, présentera lors de la H.C. Wainwright 27th Annual Global Investment Conference à New York. La présentation est prévue le lundi 8 septembre 2025, de 16h00 à 16h30 ET.
La société, qui développe des thérapies cellulaires pour des affections pédiatriques rares et des troubles chroniques liés au vieillissement, proposera la présentation en webcast. Les investisseurs pourront accéder au webcast via la rubrique "Events and Presentations" du site de Longeveron; la rediffusion sera disponible pendant 180 jours après la conférence.
Longeveron (NASDAQ: LGVN), ein Biotechnologieunternehmen in der klinischen Entwicklungsphase mit Schwerpunkt regenerative Medizin, wird auf der H.C. Wainwright 27th Annual Global Investment Conference in New York City präsentieren. Die Präsentation ist für Montag, den 8. September 2025, von 16:00 bis 16:30 Uhr ET angesetzt.
Das Unternehmen, das zelluläre Therapien für lebensbedrohliche seltene pädiatrische Erkrankungen und chronisch altersbedingte Zustände entwickelt, wird die Präsentation per Webcast bereitstellen. Investoren können den Webcast über den Bereich "Events and Presentations" auf der Website von Longeveron aufrufen; eine Wiedergabe ist für 180 Tage nach der Konferenz verfügbar.
- None.
- None.
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.
| Details for the Company’s presentation: | ||
| Date: | Monday, September 8, 2025 | |
| Time: | 4:00 – 4:30 p.m. ET | |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the H.C. Wainwright Conference 2025?
How can investors access Longeveron's (LGVN) H.C. Wainwright conference presentation?
What type of company is Longeveron (LGVN)?
Where is the H.C. Wainwright Global Investment Conference 2025 being held?
